Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905907 | 0.93 | TSHR (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19760880 | 0.79 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL15725513 | 0.79 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10168449 | 0.79 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL17358635 | 0.79 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10065668 | 0.75 | TSHR (0.47) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL12574756 | 0.71 | CTSK (0.32) | CTSK | |
| SCHEMBL12210401 | 0.71 | — | — | |
| SCHEMBL15905673 | 0.70 | — | — | |
| SCHEMBL15290265 | 0.70 | TSHR (0.32) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452144-B2 | Method of using fibrous tissue sealant | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150196496-A1 | METHOD OF USING FIBROUS TISSUE SEALANT | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2015-07-16 | — | — | US | disclosed |
| US-9017703-B2 | Method of using fibrous tissue sealant | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-8466327-B2 | Aldehyde-functionalized polyethers and method of making same | ACTAMAX SURGICAL MATERIALS, LLC (US) | 2013-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196496-A1 | METHOD OF USING FIBROUS TISSUE SEALANT | FGB, PIGS, ESD | TSHR 3510/4885CHRM2 4866/4885CHRM4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.